Domov › Nevroblastom › Texas
Klinične študije za Nevroblastom v Texas
15 študij za Nevroblastom išče udeležence na lokacijah v Texas.
Mesta v Texas
Uradno besedilo študije (angleško)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- in še 10
Vključevanje udeležencevFaza 3
Do 30 let · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Vključevanje udeležencevFaza 2
Do 22 let · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
Vključevanje udeležencevFaza 1/2
Do 26 let · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Vključevanje udeležencevFaza 1/2
Do 30 let · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Vključevanje udeležencevFaza 2
Starost 1–21 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- in še 8
Vključevanje udeležencevFaza 3
365 Days – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
Vključevanje udeležencevFaza 2
12 Months – 21 Years · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1/2
Starost 1–30 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 1–24 · Vsi spoli · Posodobljeno 21. jul. 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
Vključevanje udeležencevFaza 2
Starost 1–31 · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
Vključevanje udeležencevOpazovalna študija
31 Days – 99 Years · Vsi spoli · Posodobljeno 23. mar. 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Vključevanje udeležencev
Do 17 let · Vsi spoli · Posodobljeno 10. feb. 2026 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 1–21 · Vsi spoli · Posodobljeno 19. sep. 2025 · NCT03294954Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.